AEMD Stock Overview
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States.
Aethlon Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.35|
|52 Week High||US$5.99|
|52 Week Low||US$0.88|
|1 Month Change||33.66%|
|3 Month Change||51.79%|
|1 Year Change||-68.53%|
|3 Year Change||-65.58%|
|5 Year Change||-94.44%|
|Change since IPO||-99.98%|
Recent News & Updates
We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID
Aethlon Medical (NASDAQ:AEMD) on Monday said the U.S. FDA had approved a change in the protocol of the company's ongoing trial evaluating its blood filtration system to treat patients with severe COVID-19. AEMD said the change in protocol eliminates the inclusion criteria that patients must have a dialysis catheter in place and have tolerated dialysis at the time of screening. The trial is currently evaluating the safety and efficacy of AEMD's Aethlon Hemopurifier product. The trial is designed to enroll up to 40 severe COVID-19 patients. "We anticipate that this protocol amendment will enable us to enroll patients at an increased rate now that dialysis treatment is no longer a study requirement", said AEMD CEO Charles Fisher, Jr.
|AEMD||US Medical Equipment||US Market|
Return vs Industry: AEMD underperformed the US Medical Equipment industry which returned -21.4% over the past year.
Return vs Market: AEMD underperformed the US Market which returned -13.5% over the past year.
|AEMD Average Weekly Movement||24.6%|
|Medical Equipment Industry Average Movement||9.5%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: AEMD is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: AEMD's weekly volatility has increased from 15% to 25% over the past year.
About the Company
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer.
Aethlon Medical Fundamentals Summary
|AEMD fundamental statistics|
Is AEMD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AEMD income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.63|
|Net Profit Margin||-3,540.90%|
How did AEMD perform over the long term?See historical performance and comparison
Is AEMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AEMD?
Other financial metrics that can be useful for relative valuation.
|What is AEMD's n/a Ratio?|
Price to Book Ratio vs Peers
How does AEMD's PB Ratio compare to its peers?
|AEMD PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
PEYE Precision Optics Corporation
DCTH Delcath Systems
NMTC NeuroOne Medical Technologies
AEMD Aethlon Medical
Price-To-Book vs Peers: AEMD is expensive based on its Price-To-Book Ratio (1.3x) compared to the peer average (-0.7x).
Price to Earnings Ratio vs Industry
How does AEMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Book vs Industry: AEMD is good value based on its Price-To-Book Ratio (1.3x) compared to the US Medical Equipment industry average (2.7x)
Price to Book Ratio vs Fair Ratio
What is AEMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate AEMD's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AEMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AEMD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AEMD's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Aethlon Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AEMD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AEMD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AEMD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AEMD's revenue is expected to decline over the next 3 years (-69.8% per year).
High Growth Revenue: AEMD's revenue is forecast to decline over the next 3 years (-69.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AEMD's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Aethlon Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AEMD is currently unprofitable.
Growing Profit Margin: AEMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AEMD is unprofitable, and losses have increased over the past 5 years at a rate of 10.5% per year.
Accelerating Growth: Unable to compare AEMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AEMD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2%).
Return on Equity
High ROE: AEMD has a negative Return on Equity (-61.33%), as it is currently unprofitable.
Discover strong past performing companies
How is Aethlon Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AEMD's short term assets ($18.2M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: AEMD's short term assets ($18.2M) exceed its long term liabilities ($602.5K).
Debt to Equity History and Analysis
Debt Level: AEMD has more cash than its total debt.
Reducing Debt: AEMD's debt to equity ratio has reduced from 90.8% to 0% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AEMD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AEMD has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 17.6% each year.
Discover healthy companies
What is Aethlon Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AEMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AEMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AEMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AEMD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AEMD has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chuck Fisher (75 yo)
Dr. Charles J. Fisher, Jr., also known as Chuck, M.D. has been Chief Executive Officer of Aethlon Medical, Inc. since October 30, 2020. He serves as the Chief Executive Officer of Margaux Biologics, Inc. s...
CEO Compensation Analysis
Compensation vs Market: Chuck's total compensation ($USD2.48M) is above average for companies of similar size in the US market ($USD770.24K).
Compensation vs Earnings: Chuck's compensation has increased whilst the company is unprofitable.
Experienced Management: AEMD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: AEMD's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.1%.
Aethlon Medical, Inc.'s employee growth, exchange listings and data sources
- Name: Aethlon Medical, Inc.
- Ticker: AEMD
- Exchange: NasdaqCM
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$22.461m
- Shares outstanding: 16.64m
- Website: https://www.aethlonmedical.com
Number of Employees
- Aethlon Medical, Inc.
- 11555 Sorrento Valley Road
- Suite 203
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.